A Novel Anti-CD22 Camelid Immunotoxin Fused to Diphtheria Toxin for TargetedB-Cell Malignancy Therapy

20260 citationsJournal Article

Authors

Alireze Erfani · Pasteur Institute of Iran

Fatemeh Kazemi-Lomedasht · Pasteur Institute of Iran

Vahab Ziaei · Pasteur Institute of Iran

Sheyda Mohammadkhani · Pasteur Institute of Iran

Leila Ghazizadeh · Pasteur Institute of Iran

S. Mohammadi Motamed · Islamic Azad University Pharmaceutical Sciences Branch

Mahdi Habibi-Anbouhi

Abstract

The developed rIT is a promising candidate for targeted therapy of CD22⁺ hematologic malignancies, offering high specificity, potent cytotoxicity, and potential for reduced off-target effects.

Topics & Keywords

Toxin Mechanisms and Immunotoxins Monoclonal and Polyclonal Antibodies Research Cancer Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Current Pharmaceutical Design

Volume 32

DOI: 10.2174/0113816128432068260209055133

Field-Weighted Citation Impact: 0.00